Long-term outcomes in heart and lung transplants from HCV-viremic donors to uninfected recipients: the DONATE HCV trial
AE Woolley, HJ Goldberg, SK Singh, MR Mehra… - The Journal of Heart and …, 2021 - Elsevier
Purpose An early 6-month analysis of the DONATE HCV Trial demonstrated that hearts and
lungs can be safely transplanted from HCV-infected donors using a shortened, 4-week, pre-
emptive course of direct acting antivirals (DAA). Whether early findings are sustained in the
longer-term remain an important area of investigation. Methods DONATE HCV is a single-
center trial to transplant thoracic organs from HCV viremic donors, irrespective of HCV
genotype, to HCV-uninfected adults. Sofosbuvir/velpatasvir, a pan-genotypic DAA, was …
lungs can be safely transplanted from HCV-infected donors using a shortened, 4-week, pre-
emptive course of direct acting antivirals (DAA). Whether early findings are sustained in the
longer-term remain an important area of investigation. Methods DONATE HCV is a single-
center trial to transplant thoracic organs from HCV viremic donors, irrespective of HCV
genotype, to HCV-uninfected adults. Sofosbuvir/velpatasvir, a pan-genotypic DAA, was …
以上显示的是最相近的搜索结果。 查看全部搜索结果